WORLD HEPATITIS DAY 2020

FIND-DNDi Partnership model to enhance HCV Tx access by leveraging Dx

Jean-Michel Piedagnel, Director, DNDi South East Asia

July 30, 2020
DNDi Hepatitis C Strategy: 3 pillars

1. **Accelerate R&D**
   - Accelerating the development of promising drug candidates
   - with Pharma companies, Governments

2. **Catalyse Access**
   - Supporting affordable access to all DAAs
   - with Pharma companies, Governments, Civil Society organisations

3. **Simplify treatment strategies**
   - Working with health providers to scale up treatment
   - with Primary healthcare doctors, Non Governmental Organisations
• **DNDi work on Hep C**: Why Hep C (HCV as neglected patients)? R&D in treatment/Ravidasvir has brought in competition to provide access to affordable medicine in countries (together with other strategy such as CL, USD 80,000 to USD 300 in Malaysia)

• **DNDi-FIND collaboration**: While we running the R&D with access principle, we noticed the gap on access to diagnostic is real. MOH need evidence to change practice. Testing & diagnosis need to be on the community level instead of tertiary hospitals

• **Impact of the collaboration**:
  - primary healthcare clinics involved in Hep C diagnostic.
  - Catalyst of decentralization – with the leadership from MOH
  - Brought treatment to community clinic level
  - MOH further engagement with harm reduction CSO